Trends in Research on Gantenerumab for Alzheimer's Disease: A Bibliometric and Thematic Analysis

Gantenerumab (GR), a promising therapeutic agent for Alzheimer's disease (AD), has been the subject of extensive research. In this study, we aimed to provide a comprehensive analysis of the literature on GR.

A systematic search was conducted using the PubMed, Scopus, and Web of Science databases. VOSviewer and Bibliometrix were utilized to analyze bibliographic data.

The analysis of the literature on GR revealed distinct publication trends. Reviews accounted for 52% of the records, followed by research articles (31%). The United States contributed the highest proportion of publications (26%). The Journal of Prevention of Alzheimer's Disease was the most prolific source (21 articles). The annual number of publications increased steadily from 2009 to 2024. Major international collaborations were observed among the United States, the United Kingdom, Switzerland, France, and Sweden. Research activity consistently centered on key themes, such as amyloid imaging, biomarkers, clinical trials, and β-amyloid. Thematic mapping identified specialized subfields, core research areas, and dynamic shifts in topics, offering a comprehensive overview of the GR research landscape.

GR-related literature showed sustained thematic focus, growing international collaboration, and a steady rise in publication volume within the field of AD. These findings highlight the continued need for clinical and biomarker-focused investigations to advance therapeutic development in AD.